Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors
Serina Therapeutics (NYSE: SER) launched an enhanced corporate communications platform on October 8, 2025 to deliver timely, transparent updates to patients, clinicians, investors, and the scientific community. The platform will offer regular digital updates, educational resources, multimedia content (including a podcast), expert commentary, webinars, and online forums to support engagement.
Serina said the initiative will coincide with preparations to initiate the planned registrational study of SER-252 in Parkinson’s disease. The SER-252-1b trial is a randomized, double-blind, placebo-controlled Phase 1b with single-ascending-dose (five cohorts of eight; n=40) and multiple-ascending-dose components (up to three cohorts of 16; n=48), conducted in the U.S. and Australia to evaluate safety, tolerability, and pharmacokinetics with exploratory efficacy measures.
Serina Therapeutics (NYSE: SER) ha inaugurato una piattaforma di comunicazione aziendale potenziata il 8 ottobre 2025 per offrire aggiornamenti tempestivi e trasparenti a pazienti, medici, investitori e comunità scientifica. La piattaforma offrirà aggiornamenti digitali regolari, risorse educative, contenuti multimediali (incluso un podcast), commenti di esperti, webinar e forum online per supportare l'engagement.
Serina ha dichiarato che l'iniziativa coinciderà con i preparativi per avviare lo studio registrazionale pianificato di SER-252 nella malattia di Parkinson. Lo studio SER-252-1b è una verifica randomizzata, in doppio cieco, controllata con placebo, di Fase 1b con dose singola ascendente (cinque coorti da otto; n=40) e componenti a dose multipla (fino a tre coorti da 16; n=48), condotto negli USA e in Australia per valutare sicurezza, tollerabilità e farmacocinetica con misure esplorative di efficacia.
Serina Therapeutics (NYSE: SER) lanzó una plataforma de comunicaciones corporativas mejorada el 8 de octubre de 2025 para ofrecer actualizaciones oportunas y transparentes a pacientes, clínicos, inversores y la comunidad científica. La plataforma ofrecerá actualizaciones digitales regulares, recursos educativos, contenido multimedia (incluido un podcast), comentarios de expertos, seminarios web y foros en línea para apoyar la participación.
Serina afirmó que la iniciativa coincidirá con los preparativos para iniciar el estudio registracional planificado de SER-252 en la enfermedad de Parkinson. El ensayo SER-252-1b es un estudio aleatorizado, doble ciego, controlado con placebo, de Fase 1b con dosis única ascendente (cinco cohortes de ocho; n=40) y componentes de dosis múltiple (hasta tres cohortes de 16; n=48), realizado en EE. UU. y Australia para evaluar seguridad, tolerabilidad y farmacocinética con medidas exploratorias de eficacia.
Serina Therapeutics (NYSE: SER)는 2025년 10월 8일에 환자, 임상의, 투자자 및 과학 커뮤니티에 시의적절하고 투명한 업데이트를 제공하기 위한 강화된 기업 커뮤니케이션 플랫폼을 출시했습니다. 이 플랫폼은 정기적인 디지털 업데이트, 교육 자료, 멀티미디어 콘텐츠(팟캐스트 포함), 전문가 해설, 웨비나 및 온라인 포럼을 제공하여 참여를 지원합니다.
세리나사는 이 이니셔티브가 파킨슨병에서 계획된 SER-252의 등록 임상 연구를 시작하기 위한 준비와 일치할 것이라고 밝혔습니다. SER-252-1b 시험은 미국과 호주에서 안전성, 내약성 및 약동학을 평가하기 위해 단회증가용 용량(5개 코호트 중 8명, n=40) 및 다중증가용 용량 구성(최대 3코호트 16명, n=48)을 포함한 무작위화 이중맹검 위약 대조 1b상 연구로 탐색적 유효성 평가를 수행합니다.
Serina Therapeutics (NYSE: SER) a lancé une plateforme de communication d'entreprise améliorée le 8 octobre 2025 afin de fournir des mises à jour opportunes et transparentes aux patients, aux cliniciens, aux investisseurs et à la communauté scientifique. La plateforme offrira des mises à jour numériques régulières, des ressources éducatives, du contenu multimédia (dont un podcast), des commentaires d'experts, des webinaires et des forums en ligne pour soutenir l'engagement.
Serina a annoncé que l'initiative coïncidera avec les préparatifs en vue de lancer l'étude registrational prévue de SER-252 dans la maladie de Parkinson. L'essai SER-252-1b est une étude randomisée, en double aveugle, contrôlée par placebo, de phase 1b avec dose unique croissante (cinq cohorts de huit; n=40) et des composantes à dose multiple (jusqu'à trois cohorts de 16; n=48), menée aux États-Unis et en Australie pour évaluer la sécurité, la tolérance et la pharmacocinétique avec des mesures d'efficacité exploratoires.
Serina Therapeutics (NYSE: SER) hat am 8. Oktober 2025 eine verbesserte Plattform für Unternehmenskommunikation eingeführt, um Patienten, Kliniker, Investoren und die wissenschaftliche Gemeinschaft zeitnahe, transparente Updates zu liefern. Die Plattform wird regelmäßige digitale Updates, Bildungsressourcen, Multimedia-Inhalte (einschließlich eines Podcasts), Expertenkommentare, Webinare und Online-Foren anbieten, um das Engagement zu fördern.
Serina teilte mit, dass die Initiative mit den Vorbereitungen zur Einleitung der geplanten registrationalen Studie von SER-252 bei Parkinson einhergehen wird. Die SER-252-1b-Studie ist eine randomisierte, doppelblind, placebo-kontrollierte Phase-1b-Studie mit einer Single-Ascending-Dose (fünf Kohorten à acht; n=40) und Multi-Ascending-Dose-Komponenten (bis zu drei Kohorten à 16; n=48), in den USA und Australien durchgeführt, um Sicherheit, Verträglichkeit und Pharmakokinetik zu bewerten, mit explorativen Wirksamkeitsmessungen.
Serina Therapeutics (NYSE: SER) أطلقت منصة اتصالات مؤسسية محسّنة في 8 أكتوبر 2025 لتقديم تحديثات فورية وشفافة للمرضى والممارسين الطبيين والمستثمرين والمجتمع العلمي. ستوفر المنصة تحديثات رقمية منتظمة وموارد تعليمية ومحتوى متعدد الوسائط (بما في ذلك وكاست صوتي)، وتعليقات خبراء، وندوات عبر الإنترنت، ومنتديات على الإنترنت لدعم المشاركة.
قالت سيرينا إن المبادرة ستتزامن مع الاستعدادات لبدء الدراسة المسجّلة المخطط لها لـ SER-252 في مرض باركنسون. تجربة SER-252-1b هي تجربة عشوائية مزدوجة التعمية، محكومة بالدواء الوهمي، من المرحلة الأولى-1b مع جرعات واحدة تصاعدية (خمس مجموعات من ثمانية أشخاص؛ ن=40) ومكونات جرعات متعددة التصاعد (حتى ثلاث مجموعات من 16؛ ن=48)، أجريت في الولايات المتحدة وأستراليا لتقييم السلامة والتحمّل والدواء الفعّال والتوافر الحيوي مع مقاييس فاعلية استكشافية.
Serina Therapeutics (NYSE: SER) 于 2025年10月8日 启动了增强的公司沟通平台，以向患者、临床医生、投资者和科研界提供及时、透明的更新。该平台将提供定期数字更新、教育资源、多媒体内容（包括播客）、专家评论、网络研讨会和在线论坛，以支持参与。
Serina 表示，该举措将与为在帕金森病中开始计划的注册研究做准备同时进行。SER-252-1b 试验是一项随机、双盲、安慰剂对照的1b期研究，包含单次剂量递增阶段（五个队列，每组8人；n=40）和多次递增剂量阶段（最多三组，每组16人；n=48），在美国和澳大利亚进行，以评估安全性、耐受性和药代动力学，并设有探索性有效性指标。
- Launched comprehensive stakeholder communications platform on Oct 8, 2025
- Announced planned registrational SER-252 Phase 1b trial initiation
- Defined trial size: single-asc n=40 and multi-asc up to n=48 (up to n=88 total)
- Planned multi-country trial sites in the U.S. and Australia
- Study is early-stage Phase 1b with only exploratory efficacy measures
- Trial cohort sizes are limited (up to 88 participants), constraining efficacy conclusions
Insights
Serina expands stakeholder communications and outlines a Phase 1b registrational design for SER-252 in Parkinson's disease.
Serina Therapeutics centralizes updates via a corporate communications platform to share program, regulatory, and scientific information and will publish regular digital updates, educational material, multimedia content, and engagement events. The company describes the planned SER-252-1b randomized, double-blind, placebo-controlled Phase 1b registrational study with a single-ascending-dose portion (five cohorts of eight; n=40) and multiple-ascending-dose portion (up to three cohorts of sixteen; n=48), measuring safety, tolerability, and pharmacokinetics with exploratory MDS-UPDRS motor and structured motor-state assessments.
The platform improves transparency but does not itself change clinical risk or outcomes; program progress depends on trial initiation, safety reviews by the Safety Review Committee, and regulatory interactions across U.S. and Australian sites. Key risks remain trial safety signals, enrollment pace, and the exploratory nature of efficacy measures; communications can shape perception but not clinical or regulatory results.
Concrete items to watch: initiation and first dosing of the SER-252-1b study, Safety Review Committee decisions during dose escalation, interim safety or PK reports, and any regulatory filings or site activations in the U.S. and Australia. Expect operational updates over the next quarters following the
HUNTSVILLE, AL., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the launch of a comprehensive corporate communications platform designed to deliver timely, transparent updates to patients, clinicians, investors, and the broader scientific community.
The new initiative expands Serina’s direct channels of communication to provide stakeholders with clear, accessible information on the Company’s programs, regulatory progress, and scientific advances. The platform will feature regular digital updates, educational resources, multimedia content, and expert commentary from company leadership and scientific advisors.
“At Serina, we believe leadership in biotechnology requires not only advancing innovative science but also communicating that progress with clarity and transparency,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “As we prepare to initiate the planned trial of SER-252 in Parkinson’s disease, this new communications platform will serve as a vital resource for patients, clinicians, investors, and the broader scientific community. By providing timely updates and expert perspectives, we are ensuring that all stakeholders can follow our journey as we work to bring meaningful new treatment options to people living with Parkinson’s disease and other serious conditions.”
As part of the initiative, Serina plans to provide:
- Program and clinical updates delivered through the Company’s website and newsletters.
- Educational resources for physicians, patients, and scientists to better understand the potential of POZ-enabled therapeutics in improving therapeutic performance across multiple modalities.
- Multimedia content, including a new podcast series, to highlight perspectives from company leaders, investigators, and thought leaders in neuroscience and other therapeutic areas.
- Opportunities for engagement, including webinars and online forums to support dialogue with patient and professional communities.
This platform is designed to complement Serina’s ongoing clinical and regulatory activities, providing stakeholders with real-time access to relevant information as the Company advances its pipeline.
SER-252 Registrational Study Design Overview
The SER-252-1b study is a randomized, double-blind, placebo-controlled Phase 1b trial with single-ascending-dose (five cohorts of eight; n=40) and multiple-ascending-dose components (up to three cohorts of sixteen; n=48) in adults with Parkinson’s disease and motor fluctuations. The registrational study is designed to evaluate safety, tolerability, and pharmacokinetics of subcutaneous SER-252 versus placebo, with exploratory efficacy measures that include MDS-UPDRS motor scores and structured motor-state assessments. Dose escalation will be overseen by a Safety Review Committee and the study will be conducted across sites in the U.S. and Australia.
About SER-252 (POZ-apomorphine)
SER 252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS) via a single or twice-weekly subcutaneous injection. CDS has been shown to reduce the severity of motor fluctuations (which includes levodopa-induced dyskinesia) and enable greater daily on time, with reduced off time, in advanced Parkinson’s patients. SER-252 leverages strategic partner Enable Injections’ enFuse™ wearable drug delivery platform to enhance patient comfort and convenience, providing CDS to patients via an easy-to-administer, long-acting subcutaneous injection.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics, and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit https://serinatx.com.
For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630
FAQ
What did Serina (SER) announce on October 8, 2025?
What is the design and size of the SER-252-1b registrational study (SER)?
When and where will Serina (SER) run the SER-252 Phase 1b trial?
How can investors and patients access Serina (SER) updates and resources?
What endpoints will the SER-252 Phase 1b study evaluate for SER?
